Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Plos One|September 24, 2013
Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progressionAntonello Giovannetti, Angela Maselli, Tania Colasanti, et al.
Frontiers in Pharmacology|January 11, 2021
Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 InfectionMarta Vomero, Cristiana Barbati, Tania Colasanti, et al.
BMC Musculoskeletal Disorders|May 27, 2017
Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patientsFrancesca Romana Spinelli, Arbi Pecani, Francesco Ciciarello, et al.
Immunology Letters|June 15, 2010
Estrogen receptor profiles in human peripheral blood lymphocytesMarina Pierdominici, Angela Maselli, Tania Colasanti, et al.
Antioxidants & Redox Signaling|June 16, 2011
Gender disparity in susceptibility to oxidative stress and apoptosis induced by autoantibodies specific to RLIP76 in vascular cellsPaola Matarrese, Tania Colasanti, Barbara Ascione, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Up-regulation of autophagy by etanercept treatment results in TNF-induced apoptosis reduction in EA.hy926 endothelial cell lineCristiana Barbati, Tania Colasanti, Marta Vomero, et al.
Arthritis Research & Therapy|November 23, 2019
B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosusFrancesca Romana Spinelli, Cristiana Barbati, Fulvia Cecarelli, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Lack of cross-reactivity between rheumatoid factor IgM and anti-S1 receptor binding domain of SARS-CoV-2 IgM: a case-control studyGreta Pellegrino, Silvia Mancuso, Tania Colasanti, et al.
Frontiers in Immunology|August 4, 2018
Autophagy and Rheumatoid Arthritis: Current Knowledges and Future PerspectivesMarta Vomero, Cristiana Barbati, Tania Colasanti, et al.
Ebiomedicine|November 9, 2020
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137<sup>+</sup>T-cellsAlessio Ugolini, Ilaria Grazia Zizzari, Fulvia Ceccarelli, et al.
Pageof 5